NasdaqCM:BLTEPharmaceuticals
Belite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Value
Belite Bio (BLTE) is back in focus after announcing that new Phase 3 clinical trial results for its lead drug candidate, Tinlarebant, will be presented at major ophthalmology conferences later this year.
See our latest analysis for Belite Bio.
Belite Bio’s share price has been volatile around its clinical milestones, with a 1 day share price return of 5.04% and a 30 day share price return of 7.44%. The 1 year total shareholder return of 162.70% and 3 year total shareholder return of more than...